LEXX · Lexaria Bioscience Corp.
$2.88
-0.21 (-6.80%)
At close · Oct 2
View the 10-Q filed Jul 13, 2026
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jul 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The recurring losses and negative net cash flows raise substantial doubt as to the Company's ability to continue as a going concern. However, we have also concluded that our existing cash, combined with inflows expected from executed license agreements, will not be sufficient to meet the Company's financial obligations for the twelve-month period following the issuance of these consolidated financial statements. Accordingly, there is substantial doubt as to our ability to continue as a going concern within one year from the date of issuance of these financial statements.”View the 10-Q filed Jul 13, 2026
Customer concentration
— top customer 100% of revenue
One customer — 100% of revenue (the nine months ended May 31, 2026)
“In the nine months ended May 31, 2026, the Company recognized revenue of $20,000 on a consolidated basis. One customer accounted for 100% of that total.”
2 customers — 100% of revenue (the nine months ended May 31, 2025)
“In the nine months ended May 31, 2025, the Company recognized revenue of $531,923 on a consolidated basis. Two customers accounted for 100% of that total.”
Market Cap
$5.42M
Shares
1.65M
Volume · Oct 2
81.26K
Avg daily vol (44 sessions)
82.72K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.88
Open$3.18
Day$2.80–3.24
52W close$2.88–20.10
Avg vol 30d100K
Short int179K · 10.8% float · 1.6d
Short vol31%
DataJan 2021–Oct 2026
Filing10-Q · Jul 13
Up next
filed Jul 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$194,000
Trailing 12 months
Net income (TTM)
−$7.73M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-3,973.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$3.64M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+35.6%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
10.8%
Latest settlement · 1.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−70%
below
Price vs 50-day avg
−59%
below
RSI (14)
32
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−77%
trailing
6-month return
−80%
trailing
YTD return
−69%
this year
Relative strength
−93%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
+11% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.83% of float · ▲ +402.2% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
31 holders — near 3-yr high, broad support
Squeeze score
61
elevated · 0–100
Fundamentals
Revenue growth
+52%
Y/Y
Gross margin
100%
expanding
EPS growth
−40%
Y/Y
Free cash flow
$-10.5M
Quant / Vol
risk profile
Volatility
124%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
31.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−70%
Bearish
Price vs 50-day avg
−59%
Bearish
RSI (14)
32
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
+11% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.83% of float · ▲ +402.2% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
31 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $3 · 0%
Range high $20
vs 200-day avg -70%
vs 50-day avg -59%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LEXX
this stock
Lexaria Bioscience Corp.
|
$5.42M | — | +52.0% | — | 10.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LEXX | -12.2% | -76.6% | -80.4% | -8.6% | -68.9% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -12.0% | -76.2% | -92.6% | -9.5% | -81.7% |